Global Rules Could Cut Costs and Speed Access to GLP-1 Drugs
A study authored by Jonathan Watanabe, PharmD, MS, PhD, chair of the UCSF Department of Clinical Pharmacy, shows that aligning approval across countries could make it easier for biosimilars to reach the market — and hopefully lower costs for all patients, just like generics.